Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 364

1.

Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma.

Lorch G, Sivaprakasam K, Zismann V, Perdigones N, Contente-Cuomo T, Nazareno A, Facista S, Wong S, Drenner K, Liang WS, Amann JM, Sinicropi-Yao SL, Koenig MJ, La Perle K, Whitsett TG, Murtaza M, Trent JM, Carbone DP, Hendricks WPD.

Clin Cancer Res. 2019 Oct 1;25(19):5866-5877. doi: 10.1158/1078-0432.CCR-19-1145. Epub 2019 Aug 20.

PMID:
31431454
2.

Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2.

Gardner HL, Sivaprakasam K, Briones N, Zismann V, Perdigones N, Drenner K, Facista S, Richholt R, Liang W, Aldrich J, Trent JM, Shields PG, Robinson N, Johnson J, Lana S, Houghton P, Fenger J, Lorch G, Janeway KA, London CA, Hendricks WPD.

Commun Biol. 2019 Jul 19;2:266. doi: 10.1038/s42003-019-0487-2. eCollection 2019.

3.

Two novel genetic variants in the STK38L and RAB27A genes are associated with glioma susceptibility.

Chen H, Chen G, Li G, Zhang S, Chen H, Chen Y, Duggan D, Hu Z, Chen J, Zhao Y, Zhao Y, Huang H, Zheng SL, Trent JM, Yu L, Jiang D, Mo Z, Wang H, Mou Y, Jiang T, Mao Y, Xu J, Lu D.

Int J Cancer. 2019 Nov 1;145(9):2372-2382. doi: 10.1002/ijc.32179. Epub 2019 Mar 18.

PMID:
30714141
4.

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.

Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS.

Invest New Drugs. 2019 Aug;37(4):636-645. doi: 10.1007/s10637-018-0668-8. Epub 2018 Sep 28.

PMID:
30264293
5.

Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, Orlando KA, Lang JD, Hendricks WPD, Bally MB, Karnezis AN, Hass R, Underhill TM, Morin GB, Trent JM, Weissman BE, Huntsman DG.

Mol Cancer Ther. 2018 Dec;17(12):2767-2779. doi: 10.1158/1535-7163.MCT-18-0348. Epub 2018 Sep 19.

PMID:
30232145
6.

Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.

Hendricks WPD, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery NS, Washington M, Aldrich J, Neff MW, Huentelman MJ, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent JM.

PLoS Genet. 2018 Sep 6;14(9):e1007589. doi: 10.1371/journal.pgen.1007589. eCollection 2018 Sep.

7.

Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients.

Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Front Genet. 2018 Jul 10;9:228. doi: 10.3389/fgene.2018.00228. eCollection 2018.

8.

Evaluation of pre-analytical factors affecting plasma DNA analysis.

Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M.

Sci Rep. 2018 May 9;8(1):7375. doi: 10.1038/s41598-018-25810-0.

9.

Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.

Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM.

Clin Cancer Res. 2018 Apr 15;24(8):1932-1943. doi: 10.1158/1078-0432.CCR-17-1928. Epub 2018 Feb 9.

10.

Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis.

Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Dec 15;9(4):5044-5057. doi: 10.18632/oncotarget.23495. eCollection 2018 Jan 12.

11.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

12.

Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma.

Cornelius A, Foley J, Bond J, Nagulapally AB, Steinbrecher J, Hendricks WPD, Rich M, Yendrembam S, Bergendahl G, Trent JM, Sholler GS.

Front Pharmacol. 2017 Sep 25;8:652. doi: 10.3389/fphar.2017.00652. eCollection 2017.

13.

A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.

Choi J, Xu M, Makowski MM, Zhang T, Law MH, Kovacs MA, Granzhan A, Kim WJ, Parikh H, Gartside M, Trent JM, Teulade-Fichou MP, Iles MM, Newton-Bishop JA, Bishop DT, MacGregor S, Hayward NK, Vermeulen M, Brown KM.

Nat Genet. 2017 Sep;49(9):1326-1335. doi: 10.1038/ng.3927. Epub 2017 Jul 31.

14.

The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.

Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG.

J Pathol. 2017 Jul;242(3):371-383. doi: 10.1002/path.4912. Epub 2017 Jun 2.

PMID:
28444909
15.

Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses.

Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Apr 25;8(17):27786-27799. doi: 10.18632/oncotarget.15347.

16.

SDHD Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma.

Zhang T, Xu M, Makowski MM, Lee C, Kovacs M, Fang J, Willems E, Trent JM, Hayward NK, Vermeulen M, Brown KM.

Cancer Res. 2017 Apr 1;77(7):1649-1661. doi: 10.1158/0008-5472.CAN-16-0919. Epub 2017 Jan 20.

17.

A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters.

Kang HJ, Cui Y, Yin H, Scheid A, Hendricks WPD, Schmidt J, Sekulic A, Kong D, Trent JM, Gokhale V, Mao H, Hurley LH.

J Am Chem Soc. 2016 Oct 19;138(41):13673-13692. doi: 10.1021/jacs.6b07598. Epub 2016 Oct 5.

PMID:
27643954
18.

The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.

Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, Stewart CJR, Hendricks WPD, Cunliffe H, Huntsman DG, Pautier P, Levine DA, Trent JM, Berchuck A, Hasselblatt M, Foulkes WD.

Gynecol Oncol. 2016 Jun;141(3):454-460. doi: 10.1016/j.ygyno.2016.03.013. Epub 2016 Mar 19.

PMID:
26975901
19.

Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C.

Sci Transl Med. 2016 Feb 3;8(324):324ps5. doi: 10.1126/scitranslmed.aaf0746. Review. No abstract available.

PMID:
26843188
20.

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.

Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG.

J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21.

21.

Comparison against 186 canid whole-genome sequences reveals survival strategies of an ancient clonally transmissible canine tumor.

Decker B, Davis BW, Rimbault M, Long AH, Karlins E, Jagannathan V, Reiman R, Parker HG, Drögemüller C, Corneveaux JJ, Chapman ES, Trent JM, Leeb T, Huentelman MJ, Wayne RK, Karyadi DM, Ostrander EA.

Genome Res. 2015 Nov;25(11):1646-55. doi: 10.1101/gr.190314.115. Epub 2015 Jul 31.

22.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.

23.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

24.

An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.

Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, Tembe W, Keifer JA, Corneveaux JJ, Byron SA, Forman KM, Zuccaro C, Keats JJ, Lorusso PM, Carpten JD, Trent JM, Craig DW.

Pac Symp Biocomput. 2015:56-67.

25.

Assessing Combinational Drug Efficacy in Cancer Cells by Using Image-based Dynamic Response Analysis.

Sima C, Hua J, Cypert M, Miller T, Wilson-Robles HM, Trent JM, Dougherty ER, Bittner ML.

Cancer Inform. 2016 Mar 9;14(Suppl 5):33-43. doi: 10.4137/CIN.S30799. eCollection 2015.

26.

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K, Stark MS, Snowden H, van Doorn R, Montgomery GW, Martin NG, Keane TM, López-Otín C, Gerdes AM, Olsson H, Ingvar C, Borg A, Gruis NA, Trent JM, Jönsson G, Bishop DT, Mann GJ, Newton-Bishop JA, Brown KM, Adams DJ, Hayward NK.

J Natl Cancer Inst. 2014 Dec 13;107(2). pii: dju408. doi: 10.1093/jnci/dju408. Print 2015 Feb.

27.

Characterization of X chromosome inactivation using integrated analysis of whole-exome and mRNA sequencing.

Szelinger S, Malenica I, Corneveaux JJ, Siniard AL, Kurdoglu AA, Ramsey KM, Schrauwen I, Trent JM, Narayanan V, Huentelman MJ, Craig DW.

PLoS One. 2014 Dec 12;9(12):e113036. doi: 10.1371/journal.pone.0113036. eCollection 2014.

28.

8q24 risk alleles and prostate cancer in African-Barbadian men.

Cropp CD, Robbins CM, Sheng X, Hennis AJ, Carpten JD, Waterman L, Worrell R, Schwantes-An TH, Trent JM, Haiman CA, Leske MC, Wu SY, Bailey-Wilson JE, Nemesure B.

Prostate. 2014 Dec;74(16):1579-88. doi: 10.1002/pros.22871. Epub 2014 Sep 22.

29.

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.

Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, Andersen MT, Kiilgaard JF, Heegaard S, Sunde L, Federspiel B, Madore J, Thompson JF, McCarthy SW, Goodwin A, Tsao H, Jönsson G, Busam K, Gupta R, Trent JM, Gerdes AM, Brown KM, Scolyer RA, Hayward NK.

Clin Genet. 2015 Sep;88(3):267-72. doi: 10.1111/cge.12501. Epub 2014 Nov 6.

PMID:
25225168
30.

Assessment of PALB2 as a candidate melanoma susceptibility gene.

Aoude LG, Xu M, Zhao ZZ, Kovacs M, Palmer JM, Johansson P, Symmons J, Trent JM, Martin NG, Montgomery GW, Brown KM, Hayward NK.

PLoS One. 2014 Jun 20;9(6):e100683. doi: 10.1371/journal.pone.0100683. eCollection 2014.

31.

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.

Goodall ML, Wang T, Martin KR, Kortus MG, Kauffman AL, Trent JM, Gately S, MacKeigan JP.

Autophagy. 2014 Jun;10(6):1120-36. doi: 10.4161/auto.28594.

32.

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.

Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM.

Nat Genet. 2014 May;46(5):427-9. doi: 10.1038/ng.2928. Epub 2014 Mar 23.

33.

Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Ramos P, Karnezis AN, Hendricks WP, Wang Y, Tembe W, Zismann VL, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, Huntsman DG, Trent JM.

Rare Dis. 2014 Nov 3;2(1):e967148. doi: 10.4161/2167549X.2014.967148. eCollection 2014.

34.

A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.

Aoude LG, Wadt K, Bojesen A, Crüger D, Borg A, Trent JM, Brown KM, Gerdes AM, Jönsson G, Hayward NK.

PLoS One. 2013 Aug 19;8(8):e72144. doi: 10.1371/journal.pone.0072144. eCollection 2013.

35.

Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history.

Sun J, Na R, Hsu FC, Zheng SL, Wiklund F, Condreay LD, Trent JM, Xu J.

Eur Urol. 2013 Mar;63(3):585-7. doi: 10.1016/j.eururo.2012.11.047. Epub 2012 Dec 5. No abstract available.

36.

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.

Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.

37.

Genome-wide association study for serum complement C3 and C4 levels in healthy Chinese subjects.

Yang X, Sun J, Gao Y, Tan A, Zhang H, Hu Y, Feng J, Qin X, Tao S, Chen Z, Kim ST, Peng T, Liao M, Lin X, Zhang Z, Tang M, Li L, Mo L, Liang Z, Shi D, Huang Z, Huang X, Liu M, Liu Q, Zhang S, Trent JM, Zheng SL, Xu J, Mo Z.

PLoS Genet. 2012 Sep;8(9):e1002916. doi: 10.1371/journal.pgen.1002916. Epub 2012 Sep 13.

38.

A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.

Wadt K, Choi J, Chung JY, Kiilgaard J, Heegaard S, Drzewiecki KT, Trent JM, Hewitt SM, Hayward NK, Gerdes AM, Brown KM.

Pigment Cell Melanoma Res. 2012 Nov;25(6):815-8. doi: 10.1111/pcmr.12006. Epub 2012 Oct 1.

PMID:
22889334
39.

The BioIntelligence Framework: a new computational platform for biomedical knowledge computing.

Farley T, Kiefer J, Lee P, Von Hoff D, Trent JM, Colbourn C, Mousses S.

J Am Med Inform Assoc. 2013 Jan 1;20(1):128-33. doi: 10.1136/amiajnl-2011-000646. Epub 2012 Aug 2.

40.

Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability.

Demeure MJ, Craig DW, Sinari S, Moses TM, Christoforides A, Dinh J, Izatt T, Aldrich J, Decker A, Baker A, Cherni I, Watanabe A, Koep L, Lake D, Hostetter G, Trent JM, Von Hoff DD, Carpten JD.

Genome Med. 2012 Jul 4;4(7):56. doi: 10.1186/gm357. eCollection 2012.

41.

Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J.

Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12.

42.

Tracking transcriptional activities with high-content epifluorescent imaging.

Hua J, Sima C, Cypert M, Gooden GC, Shack S, Alla L, Smith EA, Trent JM, Dougherty ER, Bittner ML.

J Biomed Opt. 2012 Apr;17(4):046008. doi: 10.1117/1.JBO.17.4.046008.

43.

A genome-wide association study reveals that variants within the HLA region are associated with risk for nonobstructive azoospermia.

Zhao H, Xu J, Zhang H, Sun J, Sun Y, Wang Z, Liu J, Ding Q, Lu S, Shi R, You L, Qin Y, Zhao X, Lin X, Li X, Feng J, Wang L, Trent JM, Xu C, Gao Y, Zhang B, Gao X, Hu J, Chen H, Li G, Zhao J, Zou S, Jiang H, Hao C, Zhao Y, Ma J, Zheng SL, Chen ZJ.

Am J Hum Genet. 2012 May 4;90(5):900-6. doi: 10.1016/j.ajhg.2012.04.001. Epub 2012 Apr 26.

44.

Genome-wide association study identifies novel loci associated with serum level of vitamin B12 in Chinese men.

Lin X, Lu D, Gao Y, Tao S, Yang X, Feng J, Tan A, Zhang H, Hu Y, Qin X, Kim ST, Peng T, Li L, Mo L, Zhang S, Trent JM, Mo Z, Zheng SL, Xu J, Sun J.

Hum Mol Genet. 2012 Jun 1;21(11):2610-7. doi: 10.1093/hmg/dds062. Epub 2012 Feb 24.

PMID:
22367966
45.

A genome-wide association and gene-environment interaction study for serum triglycerides levels in a healthy Chinese male population.

Tan A, Sun J, Xia N, Qin X, Hu Y, Zhang S, Tao S, Gao Y, Yang X, Zhang H, Kim ST, Peng T, Lin X, Li L, Mo L, Liang Z, Shi D, Huang Z, Huang X, Liu M, Ding Q, Trent JM, Zheng SL, Mo Z, Xu J.

Hum Mol Genet. 2012 Apr 1;21(7):1658-64. doi: 10.1093/hmg/ddr587. Epub 2011 Dec 14.

PMID:
22171074
46.

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM.

Nature. 2011 Nov 13;480(7375):99-103. doi: 10.1038/nature10630.

47.

Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.

Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, Stark M, Schmid H, Holland EA, Duffy DL, Zhang M, Painter JN, Nyholt DR, Maskiell JA, Jetann J, Ferguson M, Cust AE, Jenkins MA, Whiteman DC, Olsson H, Puig S, Bianchi-Scarrà G, Hansson J, Demenais F, Landi MT, Dębniak T, Mackie R, Azizi E, Bressac-de Paillerets B, Goldstein AM, Kanetsky PA, Gruis NA, Elder DE, Newton-Bishop JA, Bishop DT, Iles MM, Helsing P, Amos CI, Wei Q, Wang LE, Lee JE, Qureshi AA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Han J, Hopper JL, Trent JM, Brown KM, Martin NG, Mann GJ, Hayward NK.

Nat Genet. 2011 Oct 9;43(11):1114-8. doi: 10.1038/ng.958.

48.

Advancing a clinically relevant perspective of the clonal nature of cancer.

Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent JM, Carpten JD, Bubendorf L, Von Hoff D, Barrett MT.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12054-9. doi: 10.1073/pnas.1104009108. Epub 2011 Jul 5.

49.

Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses.

Lu Y, Sun J, Kader AK, Kim ST, Kim JW, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J.

Prostate. 2012 Mar;72(4):376-85. doi: 10.1002/pros.21439. Epub 2011 Jun 10.

50.

High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, Mousses S, Azorsa DO.

Mol Cancer Res. 2011 Jun;9(6):724-32. doi: 10.1158/1541-7786.MCR-10-0436. Epub 2011 May 2.

Supplemental Content

Loading ...
Support Center